Keywords: Celgene, Pomalidomide, Lundbeck. Vortioxetine, Multiple myeloma, Antidepressant, USA, FDA, Europe, EMA, Canada, Japan

Regulatory briefs: Celgene's pomalidomide; Lundbeck's vortioxetine

Article | 21 September 2012

Print This

US biotech firm Celgene (Nasdaq: CELG) says that the US Food and Drug Administration’s Oncologic Drugs Advisory Committee ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in